Testing itraconazole alongside standard care for acute myeloid leukemia
Tests the antifungal drug itraconazole added to standard treatment in adults with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07069933, who can take part
Where in Egypt
- Clinical Oncology and Nuclear Medicine of Mansoura University Hospital, Mansoura,Al Mansurah, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT07069933
- Record updated
- 17 July 2025
- Original description
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of Itraconazole as an adjuvant therapy in treatment of patients with acute myeloid Leukemia.Read full original descriptionShow less
"Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?"
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of Itraconazole as an adjuvant therapy in treatment of patients with acute myeloid Leukemia.
Inclusion: Patients with Acute Myeloid leukemia, and aged 18 years or older; Patients whose ECOG performance status ranged from 0-2 and are fit for all treatments protocols.
Exclusion: Patients with any other types of malignancies rather than Leukemia and patients; Patients with documented hypersensitivity or allergy to Itraconazole; Patients suffer from chronic heart failure; Patients with history alcohol intake, acute or chronic; Patients present with severe dehydration; Patients with severe kidney dysfunction.